Canadian Medical Marijuana Firm Aurora Cannabis Expects Weak Demand In International Market

Aurora Cannabis (ACB) reported a Q4 2025 loss of CA 0.35 per share, missing estimates, while revenue beat expectations at CA 90.54 million, a 34% year-over-year increase driven by a 48% surge in global medical cannabis revenue to CA 67.8 million, which accounted for 75% of total revenue. Adjusted EBITDA increased 619% to CA 16.7 million; however, the company anticipates slightly lower global cannabis revenue in Q1 2026 due to potential drops in some international markets, though it expects positive adjusted EBITDA to continue, albeit at a reduced level compared to Q4 2025, leading to an 11.2% drop in premarket trading.

Analysis

Aurora Cannabis Inc. (ACB) reported mixed Q4 2025 financial results, characterized by a revenue beat but a significant earnings per share miss, triggering an 11.2% premarket stock decline. Sales reached CA 90.54 million, a 34% year-over-year increase and surpassing the consensus estimate of $62.04 million, largely driven by a 48% surge in global medical cannabis net revenue to CA 67.8 million; this segment now constitutes 75% of total net revenue and 88% of adjusted gross profit before fair value adjustments. This medical segment growth, particularly in Australia, Germany, Poland, and the U.K., contrasts with a 20% year-over-year decline in consumer cannabis net revenue to CA 8.2 million, attributed to a strategic prioritization of higher-margin medical products. The plant propagation business also contributed positively with a 32% revenue increase to $13.8 million. Operationally, Aurora demonstrated substantial improvement with adjusted EBITDA increasing 619% to CA 16.7 million and a consolidated adjusted gross margin of 62%. However, the company reported a quarterly loss of CA 35 cents per share, significantly missing the analysts’ estimate of an 11 cents profit per share. Looking to Q1 2026, Aurora anticipates slightly lower global cannabis revenue sequentially due to temporary international market factors but expects continued positive adjusted EBITDA, albeit reduced from Q4 2025 levels, and positive free cash flow.

Key Decisions for Investors

• Investors should weigh the strong top-line growth and significant adjusted EBITDA improvement against the substantial earnings per share miss and the subsequent negative stock price reaction.
• Carefully monitor Aurora's ability to navigate the anticipated temporary slowdown in international medical cannabis markets in Q1 2026 and its progress in expanding distribution and launching new products to reignite growth in subsequent quarters.
• Evaluate the long-term viability of the strategic shift towards prioritizing the higher-margin global medical cannabis segment, particularly its impact on overall profitability and free cash flow generation, despite the contraction in the consumer cannabis business.
• Consider the forward guidance for a decline in adjusted EBITDA from Q4 2025 levels, even while remaining positive, and its implications for near-term profitability expectations.